Depemokimab reduces exacerbation rates in patients with eosinophilic asthma without improving symptom scores
Depemokimab Reduces Asthma Exacerbations in Eosinophilic Asthma Patients
This meta-analysis evaluated the efficacy of depemokimab in patients with eosinophilic asthma compared to placebo. While the intervention si…
A new analysis shows that depemokimab can reduce the number of asthma flare-ups, though it did not significantly improve daily symptom score…
Depemokimab shows no significant difference from other biologics in reducing severe asthma exacerbations
Depemokimab Shows Similar Results to Other Biologics for Severe Asthma
This systematic review and indirect treatment comparison evaluated depemokimab against omalizumab, benralizumab, dupilumab, and placebo in p…
A new review finds that the drug depemokimab performs similarly to other established biologics in reducing severe asthma flare-ups.
Depemokimab maintains trough concentrations 90% above EC level with predicted half-life of 47 days
New data supports twice yearly dosing for asthma and sinus disease
This observational analysis of pharmacokinetic and pharmacodynamic data from Phase I and Phase III trials evaluated depemokimab in patients …
A new analysis of trial data shows a specific treatment for asthma and nasal polyps may only need to be given twice a year.